Aclarion Supports Thought Leadership at the 2nd Annual Sonntag Spine Symposium
Nociscan TM is the first evidence-supported SaaS platform to objectively measure discogenic biomarkers for insight into pathological pain.
Nociscan provides decision support to help bridge a major diagnostic void.
Robert Eastlack, MD will speak to his real-world experience using Nociscan to effectively evaluate CLBP.
BROOMFIELD, CO , Feb. 15, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain (CLBP), announced today their presence at the 2nd Annual Sonntag Spine Symposium on Friday, February 17, hosted by Barrow Neurological Institute. Aclarion executives, Jeff Thramann, Brent Ness, and Ryan Bond, will be attending the meeting with industry-leading physicians, including Aclarion advisors Juan Uribe, MD and Robert Eastlack, MD.
Barrow Neurological Institute (BNI) at Dignity Health St. Joseph’s Hospital and Medical Center in Phoenix, Arizona is an international leader in the treatment, research, and education of brain and spinal diseases, conditions, and injuries. “More than thirty key opinion leader physicians will be together discussing, debating and educating the most provocative topics in spine care,” said Juan Uribe, MD, Vice Chair, Chief of Spine Surgery at BNI.
Globally, 266 million people suffer from generative spine disease and low back pain. Of all the disease states, back and neck pain account for the highest healthcare spending in the US. Aclarion’s Nociscan solution is the first evidence-supported SaaS platform to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine. Nociscan objectively quantifies chemical biomarkers demonstrated to be associated with disc pain. Biomarker data is entered into proprietary algorithms to highlight if a disc may be a source of pain. When used with other diagnostic tools, Nociscan provides critical insights into the location of a patient’s low back pain, giving physicians clarity to optimize treatment strategies.
“I was introduced to Aclarion’s pioneering innovation several years ago,” said Robert Eastlack, MD, Division Head, Spine Surgery, Scripps Clinic Medical Group. “To see Nociscan evolve and address one of the biggest problems in our industry – objectively measuring discogenic biomarkers for insight into pathological pain– is helping me help my patients with critical information never-before available.”
About Aclarion, Inc.
Aclarion is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (“MRS”), proprietary signal processing techniques, biomarkers, and augmented intelligence algorithms to optimize clinical treatments. The Company is first addressing the chronic low back pain market with Nociscan, the first, evidence-supported, SaaS platform to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine. Through a cloud connection, Nociscan receives magnetic resonance spectroscopy (MRS) data from an MRI machine for each lumbar disc being evaluated. In the cloud, proprietary signal processing techniques extract and quantify chemical biomarkers demonstrated to be associated with disc pain. Biomarker data is entered into proprietary algorithms to indicate if a disc may be a source of pain. When used with other diagnostic tools, Nociscan provides critical insights into the location of a patient’s low back pain, giving physicians clarity to optimize treatment strategies.
For more information, please visit www.aclarion.com .
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 about the Company's current expectations about future results, performance, prospects and opportunities. Statements that are not historical facts, such as "anticipates," "believes" and "expects" or similar expressions, are forward-looking statements. These forward-looking statements are based on the current plans and expectations of management and are subject to a number of uncertainties and risks that could significantly affect the Company's current plans and expectations, as well as future results of operations and financial condition. These and other risks and uncertainties are discussed more fully in our filings with the Securities and Exchange Commission. Readers are encouraged to review the section titled "Risk Factors" in the Company's Prospectus dated April 21, 2022, as filed with the Securities and Exchange Commission on April 25, 2022 under Rule 424(b)(4), as well as other disclosures contained in the Prospectus and subsequent filings made with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date and the Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Kirin M. Smith
PCG Advisory, Inc.